If you invest in the stock market, you must know the Dr Reddy share price targets for 2026, 2027, 2028, 2029, 2030, 2040, and 2050. Here, you will get detailed information regarding all your queries, such as its fundamentals, shareholdings, financial performance, future predictions, and more.
About Dr Reddy’s Laboratories Ltd.
Dr. Reddy’s Laboratories is a pharmaceutical company of India that makes and sells important medicines used to treat common and serious health problems. It provides affordable generic medicines, OTC drugs, and active pharmaceutical ingredients (APIs) used in hospitals and homes around the world. The company is known for making high-quality cancer, heart, and infection medicines, and also helps bring low-cost treatment options to people in India and other countries. Dr. Reddy’s is trusted for its safe, FDA-approved drugs, and is one of the top names in the healthcare and pharma industry.
Fundamental Analysis of Dr Reddy
- Market Cap: ₹1,02,846 Cr.
- High / Low: ₹1,380 / ₹1,121
- Stock P/E: 18.5
- Book Value: ₹432
- Dividend Yield: 0.65%
- ROCE: 22.7%
- ROE: 18.0%
- Face Value: ₹1.00
Dr Reddy Share Price Target 2026
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹1200 and potentially achieve a maximum target of ₹1300 in the year 2026.
Dr Reddy Share Price Target 2027
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹1300 and potentially achieve a maximum target of ₹1400 in the year 2027.
Dr Reddy Share Price Target 2028
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹1400 and potentially achieve a maximum target of ₹1500 in the year 2028.
Dr Reddy Share Price Target 2029
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹1500 and potentially achieve a maximum target of ₹1700 in the year 2029.
Dr Reddy Share Price Target 2030
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹1700 and potentially achieve a maximum target of ₹1900 in the year 2030.
Dr Reddy Share Price Target 2040
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹5900 and potentially achieve a maximum target of ₹6300 in the year 2040.
Dr Reddy Share Price Target 2050
After analysing past price trends and market performance, it is estimated that the Dr Reddy stock price could reach a minimum of ₹16100 and potentially achieve a maximum target of ₹16600 in the year 2050.
Shareholding Pattern of Dr Reddy
- Foreign Institutions: 33.22%
- Promoters: 26.64%
- Other Domestic Institutions: 16.57%
- Mutual Funds: 13.87%
- Retail and Others: 9.71%
Should You Invest in Dr Reddy’s Laboratories Stock?
| Year | Target Price (₹) |
|---|---|
| 2026 | 1200–1300 |
| 2027 | 1300–1400 |
| 2028 | 1400–1500 |
| 2029 | 1500–1700 |
| 2030 | 1700–1900 |
| 2040 | 5900–6300 |
| 2050 | 16100–16600 |
Whether you should invest or not, it depends on the many factors. Let us know the risk and opportunities to invest in Dr Reddy’s Laboratories stock.
Opportunities
- Dr. Reddy’s is a leading Indian pharmaceutical company with strong global presence, especially in the US and Europe, boosting export revenue.
- The company focuses on generic drugs, which are high in demand due to rising healthcare needs and lower costs.
- With ongoing investments in research and development (R&D), it continues to launch new medicines and treatments for chronic diseases.
- Dr. Reddy’s has a strong balance sheet and low debt, making it a financially stable stock for long-term investment.
- The global push for affordable healthcare offers long-term growth potential for Dr. Reddy’s in emerging and developed markets.
Risks
- The pharma industry is highly regulated, and any change in global drug approval rules can affect the company’s profits.
- Heavy dependence on the US market means earnings can be hit by price cuts or policy changes in the US healthcare system.
- Rising competition in generic drugs can lower prices and reduce profit margins for the company.
- Any failure or delay in drug approvals may directly impact stock performance and investor confidence.
- Currency fluctuations, especially in the rupee vs. dollar, can affect overseas earnings and quarterly results.
Key Competitors of Dr Reddy
Key competitors or peer companies of Dr Reddy are Sun Pharmaceutical Industries, Cipla, Lupin, Aurobindo Pharma, Torrent Pharmaceuticals, Glenmark Pharmaceuticals, Zydus Lifesciences, Biocon, Cadila Pharmaceuticals, Alkem Laboratories, Divi’s Laboratories, Wockhardt, Natco Pharma, Jubilant Pharmova, and Alembic Pharmaceuticals.
Disclaimer: All the information provided in this article is for educational purposes only. DateUpdateGo always advises seeking guidance from a certified financial advisor before making any investment-related decisions.
